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Abstract

Christina L. Chrom
COMBINATORIAL EFFICACY OF ANTIMICROBIAL PEPTIDES AND SILVER
IONS
2016-2017
Gregory A. Caputo, Ph.D.
Master of Science in Pharmaceutical Science

Antimicrobial peptides are produced by multicellular organisms as a defense
against competing pathogenic microbes. The mechanism of action for positively charged
antimicrobial peptides is widely believed to occur when the positively charged peptide
interacts with the negatively charged outer lipid membrane followed by the insertion of
the peptide into the membrane. This insertion into the outer or cytoplasmic membranes
leads to disruption of membrane integrity. Alternatively, silver based antimicrobials,
which have been well known for centuries, are thought to act by inhibiting the proton
motive force, the respiratory electron transport chain, and by affecting membrane
permeability resulting in cell death. Considering the different proposed modes of action,
we investigated the combination of these two antimicrobial species in an attempt to
enhance efficacy by targeting different cellular processes. We performed biophysical and
microbiological characterization using fluorescence spectroscopy, circular dichroism
(CD) spectroscopy, vesicle permeabilization assays, bacterial permeabilization assays,
and minimal inhibitory concentration (MIC) assays. While all five peptides tested in this
study exhibited binding to model lipid membranes, the truncated peptides showed no
measurable antimicrobial activity. The most active peptide proved to be the parent
peptide AP3 with the highest degree of leakage and bacterial membrane permeabilization.
v

Moreover it was found that the ability to permeabilize model and bacterial membranes
correlated most closely with the ability to predict antimicrobial activity. The mechanism
of enhancement is under investigation along with expansion to other strains and various
other antimicrobial peptides. Combinatorial delivery of antimicrobials with different sizes
and modes of action appears to be a promising approach while minimizing potent toxicity
and resistance concerns.
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Chapter 1
Overview of Antimicrobials
Background
History of antimicrobials. Since ancient history, natural products were often
used as a means of treating a variety of human conditions and earliest records include
using natural derived compounds for specific health conditions. This included using a
variety of natural sources and remedies for bacterial infections, which at the time were
not previous known to be caused by bacteria. Consistent with this, natural products have
been and continue to be a major source of drug discovery, especially for
antibiotics[1],[2]. The golden age of antibiotics began in 1930s with the discovery and
development of penicillin, a natural product, by Alexander Fleming[2, 3]. Shortly after
this development other common antibiotics, including streptomycin, chloramphenicol and
tetracycline, emerged[3]. The majority of antibiotics that are still in clinical use were
discovered between 1940 to 1980 and are natural products or natural product-derived
compounds[1].
Antibiotics are one of the most commonly prescribed classes of drug but around
50% are considered to be unnecessarily prescribed or others are not given the appropriate
treatment[4],[5]. This overuse and misuse has contributed to the global problem of
antibiotic resistance[4-6]. There are more than 70% of pathogenic bacteria are resistant to
at least one antibiotic that is currently on the market[7, 8]. Antibiotic resistant bacteria
have been isolated from both hospital and community settings where they have caused
serious life-threatening illnesses[9]. As a direct result of these antibiotic resistant bacteria
around 23,000 deaths occur per year (Figure 1). If this global crisis continues to increase,
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and if actions are not taken to decrease the ongoing problem, the world might return to a
preantibiotic-era in which common infections may become severe[8] [10].
There are several ways that bacteria develop resistance including genetic mutation
and modification of existing or new genetic material[6]. Resistant strains therefore have a
competitive advantage in an infection when antibiotics are prescribed[5]. After the
development of resistance, bacteria can then pass the resistance genes to its progeny or
other bacteria[6, 11]. This transfer can occur through bacteriophage-mediated transfer of
DNA, DNA taken up from the external environment or DNA transfer by cell-to-cell
contact[6]. Bacterial biofilms are another method by which bacteria can become resistant
to antibiotic[9]. Biofilms formation occurs through the adhesion of bacteria to a surface
which leads to colonization of bacteria in a matrix of extracellular polymeric
substances[12, 13]. This biofilm formation is able to protect the microorganism against
antibiotics that would normally eliminate the much less dense planktonic cell[9, 12]. It is
believed that 60% of bacterial infections and up to 80% of chronic infections occur as a
result of bacterial growth within biofilms[14, 15]. Because of this increasing problem of
resistance for antibiotics and other antimicrobial it has become critical to try and
discovery new strategies for antimicrobial treatments.
Early and present uses of silver as an antimicrobial. Historical evidence shows
that silver has been used as early 4,000 B.C.E. in health and medicine[16]. These include
blood purification, treatment of skin ulcers, and preservation of food and water[16].
Until the wide spread development of antibiotics in the 1940s, electric colloids of silver
were used as the foundation of antimicrobial therapy[16]. Within recent years, antibioticresistant bacteria have proliferated necessitating the development of alternative strategies
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to combat infection caused by these resistant bacteria[17, 18]. Silver has been found to be
one class of molecules that have a low propensity for resistance development. The longstanding application of silver as an antimicrobial, combined with the antibiotic resistance
bacteria has the investigation as a potential tool or component of combinatorial therapies
to address this emerging threat. Recent reports describe silver being used for skin ulcer
treatment, wound treatment, dental hygiene, catheters and compound fracture[16, 18, 19].
There are various formulations and delivery routes for biomedical applications of
silver. However it is widely believed that the ionic form (Ag+) is known to be responsible
for the antimicrobial activity. However there is still no definitive mechanism of action
for the antimicrobial activity of Ag+. Several proposed mechanisms that are thought to
be responsible for the antimicrobial activity including enzyme deactivation through thiol
reactivity, disruption of the electron transport chain, cell membrane disruption,
interaction with bacterial cell DNA, and destruction of bacterial cells by free-radicals[19,
20].
Silver resistance in bacteria. With silver being used throughout history, there
have been some reports of silver resistance development in bacteria. These resistant
bacterial strains have been isolated in hospital settings[21],[22]. There are several genes
carried on bacterial plasmids responsible for resistance to silver[21]. The molecular
mechanism of resistance involves a periplasmic metal-binding protein, a chemiosmotic
efflux pump and ATPase efflux pump[23]. These plasmid-encoded pumps, which
actively transfer the Ag+ out of the cell, are thought to be a major sources of the silver
resistance[23],[24]. The development of silver resistance is not very widespread which
can be attributed to the broad-spectrum activity and the proposed mechanisms of action,
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which target multiple bacterial components[25]. Although resistance to silver can
develop, the rate of development appears to be slower than for other antimicrobial agents,
which still gives promise to future development of silver based antimicrobial
therapies[22].
Antimicrobial peptides used as an antimicrobial agent. Another class of
molecules that have low propensity for resistance is antimicrobial peptides (AMPs).
Antimicrobial peptides are biomolecules that have been conserved through evolution and
are found in all complex living organisms[26],[27]. There is significant diversity in
peptides that exhibit antimicrobial activity. One of the most well studied classes are those
which

are

ribosomally

mechanism[28],[29],[30] .

synthesized

as

part

of

the

natural

host

defense

AMPs are widely used as a defense mechanism in

multicellular organisms and are often produced to play an important role in innate
immune systems and the host defense mechanism[31],[32],[33],[34]. As such, bacteria
have been exposed to AMPs throughout millions of years of evolution yet there has not
been any significant development of resistance[35]. This low propensity for resistance
and ability to kill or inhibit bacterial growth has made AMPs an ideal target for new drug
discovery to help combat antibiotic resistant bacteria[26],[35].
Naturally occurring antimicrobial peptides are gene-encoded, ribosomally
synthesized polypeptides[36]. These peptides are usually short (fewer than 100 amino
acid residues), have a positive net charge, amphipathic nature, and often exhibit a broad
spectrum of activity against bacteria, viruses and fungi[26],[37],[38]. Because of the wide
sequence and structural diversity, AMPs are traditionally classified based on secondary
structure conformations: α-helices, β-sheets or random coils[26]. There are several well-
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known examples of antimicrobial peptides belonging to the families of the
cathelicidins[31] and defensins[31], both of which are derived from vertebrates and
invertebrates. Other examples include plant-derived thionins[39], insect-derived
cecropins[40] and amphibian-derived magainins[41].
Mechanism of action of cationic antimicrobial peptides. The mechanism of
action for cationic antimicrobial peptides isn’t fully understood. The majority of
hypotheses on the mechanism of action begin with the positively charged peptide
interacting with negatively charged bacterial cell surface[26],[35],[37]. This interaction is
followed by the insertion of the peptide into the membrane leading to disruption of the
lipid bilayer. This process is thought to be driven by the partitioning of hydrophobic
amino acid side chains in the nonpolar core of the bacterial membrane. While it is
difficult to investigate in bacterial systems, using model membrane vesicles approaches,
the binding and insertion of the AMPs into the bilayer is often concomitant with
secondary structure rearrangement in the peptide.
There are several physical models that have been proposed for the membrane
disruptive activity of AMPs. The barrel stave model involves the insertion of the peptide
into the membrane which forms a purely proteinaceous pore[42]. In the toroidal pore
model, AMPs cause bending of the lipid membrane leading to the formation of a protein
and lipid headgroup-lined pore. In the carpet model AMPs cause destabilization of the
cell membrane through a mass action effect similar to a micellization type
mechanism[43].
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Antimicrobial peptides derived from venoms and toxins. While many
antimicrobial peptides are naturally occurring components of the innate immune system
of higher organisms, other naturally occurring peptides can also exhibit antimicrobial
activity. Naturally occurring venoms and toxins often contain a cocktail of biologically
active molecules and have been a rich source for the identification of antimicrobial
peptides. Many of these peptides function naturally to damage cell membranes as part of
the mechanism of action of the venom. Animal venoms and toxins have an evolutionary
pressure to increase its defense and ability to improve prey capture[44]. Due to this
diversity, peptides from naturally occurring venoms and toxins have become an area of
interest because they interact with a wide variety of molecular targets.[44] Wellcharacterized examples include the honeybee venom peptides melittin[45], wasp peptides
MP1 and mastoparan, and the rattlesnake toxin crotamine[46].
Cationic antimicrobial peptide decoralin. Venomous arthropods often produce
venom mixtures that include peptides with antimicrobial activity. These complex venoms
are naturally used to suppress prey[47]. The venom of the solitary eumenine wasp,
Oreumenes decoratus (Figure 2) is a mixture that includes an 11 residue peptide with is
commonly referred to as decoralin[33]. Decoralin has been characterized as a linear,
cationic alpha-helical peptide consisting of hydrophobic and basic amino acids[33].
Synthetic analogs of the original decoralin sequence have been characterized and the
biological activities investigated. In a study preformed by Konno et al., the C-terminus of
decoralin was amidated, resulting in higher levels of helicity and decreased hemolytic
activity when compared to the original sequence[33]. The amidated analog of decoralin
also showed greater antimicrobial activity against both Gram positive and Gram negative
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bacteria[33]. These results show a great potential for decoralin analogs being a good
template for new drug targets in combating antibiotic resistance.
Cationic antimicrobial peptide AP3. Antimicrobial peptides isolated from
different species of fish have become a focus of research because fish abundantly express
peptides as defense mechanism after hatching[48],[49]. Pleurocidins are a class of
antimicrobial peptides that have been isolated from a variety of Atlantic flounder species
including the winter flounder Pleuronectes americanus (Figure 3)[48],[50],[51]. In a
study performed by Patrzkat et.al., several peptide products were isolated from the
Winter flounder, including the peptide AP3. AP3 showed one of the highest antimicrobial
activities of all the sequences tested and had the greatest effect on P. aruginosa indicted
by the minimal inhibitory concentration (MIC) performed in this same study[48].
Introduction of synergy as a solution to antibiotic resistant bacteria. There are
three possible combinatorial effects: additive, antagonistic, or synergistic[52].

An

additive effect is one in which the effects of each agent is identical whether they are
combined or singular but when combined the two effects stack[52]. An antagonistic
effect is one in which the overall effect is diminished when the two entities are mixed,
often through inhibition or competition[52]. Synergy is defined by two or more entities
having a positive attribute when the entities are combined[53]. Therefore a synergetic
effect is one in which there is a greater effect together than the individual species
alone[53].
The challenge of antibiotic resistance has renewed interest in exploring
combinatorial therapies using previously identified antimicrobial agents in the hope of
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identifying synergistic interactions. In a study performed by Guozhi et al., two or three
AMPs were combined in order determine potential synergistic effects[52]. This study
found that both two-AMP and three-AMP combinations showed strong synergistic
interactions[52]. These results show the promising outcome of AMPs being used in
combination with other antimicrobial agents to produce a synergistic effect[52]. A similar
study performed by Choi et al. tested the AMP arenicin-1 with various bacteriostatic
antibiotics[54]. The study found that in almost all bacteria species tested there was a
strong synergistic effect using the fractional inhibitory concentration index (FICI)[54].
These results show that the ability of bacteriostatic antibiotics and formally ineffective
concentration of the peptide could be restored[54].

Figure 1. Superbugs vs. Spiders[55]
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Figure 2. Solitary Eumenine Wasp, Oreumenes decoratus.[56]

Figure 3. Winter Flounder Pleuronectes americanus.[56]
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Figure 4. Schematic of Peptide Pore Formation. The schematic represents an AMP (1)
transitioning from the water to the lipid bilayer, followed by (2)the peptide folding into
an α-helical conformation on the surface of the bilayer. (3) The peptide then inserts into
the bilayer to form a pore or other bilayer disruptive structure, therefore compromising
the integrity of the membrane.
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Chapter 2
Characterization and Antimicrobial Activity of Amphiphilic Peptide AP3 and
Derivative Sequences
Introduction
Antimicrobial peptides isolated from different species of fish have become a
focus of research because fish are abundant in peptides as defense mechanism after
hatching[48],[49]. Pleurocidins are a class of antimicrobial peptides that have been
isolated from a variety of Atlantic flounder species, including the winter flounder
Pleuronectes americanus[48],[50],[51]. In this study, different analogs of the Pleurocidin
like peptide AP3, from P. americanus, were synthesized to further investigate the
sequence-structure and activity relationship in these peptides. Different analogs of AP3
were synthesized in which length, charge identity, and Trp position were varied.
Different analogs of the peptide AP3 were synthesized to further investigate the
sequence-structure and activity relationship. Table 1 lists the parent and analogs peptides
that were tested along with their sequences. The AP3K analog has a modified sequence
that replaces the single arginine at position 3 with a lysine. This construct was
synthesized to create a uniform charge and cationic functional throughout the entire
peptide. The APX analog switches the position of the tyrosine normally at position 22
with the tryptophan, which is normally at position 2. This construct was designed to
facilitate the incorporation of tryptophan in later constructs, as tryptophan is a good
reporter in fluorescence assays and solid phase peptide synthesis proceeds from the C to
N terminus. Thus allowing tryptophan to be incorporated into constructs of varied
lengths. This facilitated the synthesis of truncated versions of APX consisting of either
the 12 or 17 C-terminal fragments, APX-12 and APX-17 respectively. The peptides were
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characterized using fluorescence spectroscopy to analyze bilayer interactions, circular
dichroism to determine secondary structure, and a variety of membrane permeabilization
assays.

Table 1
Peptide Sequences
Molecular Weight
Sequence

Measured

Calculateda

Net
Chargea

pIa

AP3

GWRTLLKKAEVKTVGKLALKHYL

2652.8

2653.2

+5

10.89

AP3K

GWKTLLKKAEVKTVGKLALKHYL

2617.8

2625.2

+5

10.74

APX

GYRTLLKKAEVKTVGKLALKHWL

2653.2

2653.2

+5

10.89

APX17

KKAEVKTVGKLALKHWL

1950.2

1949.3

+4

10.85

APX12

KTVGKLALKHWL

1393.7

1394.7

+3

10.98

Peptide

a: Calculated using Innovagen Peptide property calculator http://pepcalc.com/
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(A)

(B)

(C)

(D)

(E)

Figure 5. Helical Wheels of (A) AP3 and Derivative Sequences (B)AP3K, (C)APX,
(D)APX-17, and (E)APX-12. Circles represent hydrophilic residues, diamonds as
hydrophobic residues, anionic as triangles, and cationic as pentagons. Projections were
made using http://rzlab.ucr.edu/scripts/wheel/wheel.cgi
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Materials and Methods
Peptide preparation. The peptides APX, APX-17, and APX-12 were prepared
by FMOC solid phase synthesis. Synthesis was performed on rink-amide resin using
Fmoc-protected amino acids, HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3triazolo[4,5-b]pyridinium

3-oxid

hexafluorophosphate),

and

DIEA

(N,N-

Diisopropylethylamine) at a 1:1:2 ratio for couplings. Deprotections were performed
using a solution of 1:4 v:v: piperidine in DMF (N,N-Dimethylformamide). Cleavage was
performed by mixing the resin with a cocktail of TFA (trifluoroacetic acid):TIS
(triisopropylsilane):H2O:ETHANEDITHIOL (92.5:2.5:2.5:2.5) for ~2 h followed by
filtration and peptide precipitation in cold diethyl ether.

Remaining peptides were

purchased from GenScript (Piscataway, NJ). All peptides were purified by reverse phase
high-performance liquid chromatography using a linear gradient of solvent A (H20 with
0.1% TFA) and solvent B (acetonitrile with 0.1% TFA). Peptides were separated on an
Agilent (5 μm 9.4x250 mm) C4 column. Fractions were monitored using UV absorbance
at 220 and 280 nm and peptide identity was confirmed using ESI-MS (Agilent 1100
Series LC/MSD Trap). Purified peptides were lyophilized, reconstituted in an ethanol
water mixture and stored at 4 °C. Peptide stock concentration was determined
spectrophotmetically as described previously.[57] [58]
Bacterial culturing. Bacteria were streaked from frozen stocks onto LB - miller
agar (Difco) plates (E. coli MG1655 ATCC 47076, E. coli D31[59], S. aureus
ATCC25923, P. aeruginosa ATCC10145, K. pneumoniae 700603).
were grown overnight at 37 °C and subsequently stored at 4 °C.
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Streaked plates

To prepare overnight cultures, a single colony of each bacterial strain was added
to LB broth (Difco) in sterile culture tubes. Tubes were placed in the shaking incubator at
37 °C overnight to allow for sufficient bacterial growth. After incubation, dilutions of the
overnight culture were made in Muller-Hinton broth (Criterion) 1:100 or 1:250 for MIC
(minimal inhibitory concentration) assay protocols.
Minimum inhibitory assay (MIC). Minimal inhibitory concentrations (MIC)
were determined for each peptide The MIC plate was made by adding 10 μL of the
peptide stock solutions to wells of a sterile 96-well plate to which 90 μL of diluted
bacterial culture was added. The final bacterial load was ~5.0 x 105 cfu/mL as calculated
from OD600 measurements of a log-phase culture. The assay plate was incubated at 37 °C
for 18 h. Bacterial growth was assayed by absorbance at OD600 using Multiskan
microplate reader (Thermo Fisher). The MIC was defined as the lowest peptide
concentration to completely inhibit growth as judged by the absorbance at 600 nm
compared to controls. All MIC values are averages of at least triplicate samples.
Lipid preparation. Stocks of POPC (1-palmitoyl-2- oleoyl-sn-glycero-3phosphocholine)

and

POPG

(1-palmitoyl-2-

oleoyl-sn-glycero-3-phospho-(1’-rac-

glycerol) (Avanti Polar Lipids) were dissolved in chloroform and stored at -20 °C.
Vesicles were prepared by mixing appropriate aliquots of lipids in a glass test tube which
were dried first with nitrogen gas and then under a vacuum for 1 h. Small unilamellar
vesicles (SUVs) were formed by resuspending the lipid film in PBS buffer (50 mM
sodium phosphate, 100 mM NaCl, pH 7.1) before sonicating in a high power bath
sonicator for 18 min (Avanti Polar Lipids).
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Binding experiments. Peptide binding to lipid vesicles was determined using
fluorescence spectroscopy by titrating in aliquots of lipid vesicles into a sample that
contained buffer and peptide. Lipid vesicles were prepared as described above with either
100% POPC (PC) or 75:25 POPC:POPG (PC:PG) lipid composition and final peptide
concentration of 2 μM. Trp Emission spectra were recorded from 300 to 400 nm with an
excitation of 280 nm using a Spectramax-2 spectrofluorometer (JY-Horiba, Edison NJ).
All spectra were recorded at 25 °C.
Acrylamide quenching. Samples for acrylamide quenching analysis composed of
250 μM total lipid and 2 μM peptide. Samples were excited at 295 nm with emission
measured over the range of 315–415 nm. Fluorescence measurements were taken prior to
addition of quencher as the F0 value. Aliquots from a 4M stock of acrylamide in water
were added to the samples, mixed, and then remeasured. All spectra were recorded at 25
°

C. Fluorescence from background samples containing only lipid vesicles, buffer and

quenchers were subtracted. Emission intensity was also corrected for dilution by addition
of the quencher and for inner filter effects by the quencher as described previously[58].
Circular dichroism. Samples were prepared in a buffer containing 1:10 diluted
PBS (5 mM phosphate, 10 mM NaCl, pH 7.04) with peptide concentration of 5 μM
unless specified otherwise. A Jasco J-715 CD spectrometer was used to record circular
dichroism (CD) spectra using a quartz cuvette with a 1 cm path length. All spectra were
recorded at 25 °C and averaged over 64 scans.
Calcein leakage assay. Lipid films were prepared as described as above for a
final concentration of 20 mM (75% POPC, 25% POPG). Lipid films were rehydrated
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with 46 mM calcein in 33 mM HEPES, pH 7. After being fully dissolved the sample was
subjected to 11 freeze-thaw cycles by transferring between liquid nitrogen followed by 37
°

C water bath. Vesicles were then extruded by passing the solution through 0.2μM

polycarbonate filters for 21 passes to create large unilamellar vesicles (LUVs). Extruded
LUVs were separated from free calcein using size exclusion column chromatography
(Sephadex G-100). Lipid concentrations and dilution factors were determined
spectroscopically using a fluorescent reporter lipid. Assays were performed in a 96 well
plate was set up to such that each well contained lipid, 15 μL peptide diluted from a stock
for appropriate final concentration in the wells, and HEPES buffer to a final volume of
150 μL. Complete calcein release was achieved by adding 5 μL of 170 mM Triton X-100
to each well at the end of the experiment. All data were normalized to the 100% release
value according to the intensity after the Triton X-100 treatment. All experiments were
performed at least in triplicate.
Bacterial outer membrane permeabilization assay. Bacterial culturing was
performed as described above with the exception that E. coli (E. coli D31) was streaked
onto LB-agar plates supplemented with 100 μg/mL Ampicillin. The overnight cultures
and dilutions were grown in the presence of ampicillin at a final concentration of 100
μg/mL. After dilutions were grown to OD600 ~0.2 - 0.3, cells were then centrifuged at
2500 rpm for 15 mins and pellet was resuspended in PBS (100 mM phosphate, 200mM
NaCl, pH 7.0). The permeabilization assays were carried out using a 96-well clear flat
bottom plate with wells containing 10 μl of 500 μg/mL nitrocefin, 80μL of resuspended
E. coli cell suspension, and 10 μL of peptide at various concentrations. A 0.25 mM
solution of polymyxin B sulfate was used as a positive control.

17

Immediately after

addition of peptide the nitrocefin cleavage was monitored by absorbance at 486 nm in 5
minute intervals for 1.5 h. Experiments were performed at least in triplicate.
Bacterial inner membrane permeabilization assay. Bacterial culturing was
performed as mentioned above with the exception that E. coli (D31) was used and 50 μL
of 100 mM IPTG was added to the cultures after dilution. The permeabilization assays
were carried out using a 96-well clear flat bottom plate with wells containing 56.25 μL Zbuffer (100 mM Na2HPO4, 10 mM KCl, 1 mM MgSO4, 40 mM β– mercaptoethanol, pH
7.1), 12 μL ONPG (4mg/ml), 18.75 μL E. coli, (5.0 x 105 cfu/ml) and 10μL of peptide or
the cationic detergent CTAB as a control. After these additions the ONPG cleavage was
monitored by absorbance at 420 nm in 5 minute intervals for 1.5 h. All experiments were
performed at least in triplicate.
Measurement of cell viability. Cellular toxicity of specific peptides was
determined by MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide))
assay. Human embryonic kidney (HEK) 293 cells with a lenti-CRE luciferase reporter
gene were seeded in 96-well plates at a density of 1.5x104 cells per well and incubated
with 5% CO2 at 37 °C for 24 h. Then, cells were treated with appropriate concentrations
of peptides (0.0015-15µM) and control for 24 h. After treatment for 24 h, 10 µL of MTT
solution (5 mg MTT/ mL PBS) was added to all wells and incubated for 4 h. Then,
DMSO was added as a solubilizing agent and the absorbance was recorded at 540 nm.
Each peptide concentration was performed in triplicate.
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Results
Minimum inhibitory concentration (MIC). The antibacterial activities of each
peptide were determined against various Gram-negative and Gram-positive bacteria using
MIC assays. The MIC is defined as the lowest concentration of peptide that prevents
growth of bacteria using the optical density at 600 nm under standard growth
conditions[60]. The parent peptide AP3 shows equal or greater antimicrobial activity
against all organisms tested when compared to the other full length and truncated analogs
(Table 2). AP3 had the lowest MIC (highest activity) against P. aeruginosa exhibiting an
MIC of approximately 0.3 μM. The AP3K variety exhibited a profile similar to the parent
AP3 with no more than a two-fold difference against any strain tested. The APX variant
showed very weak antimicrobial activity, only exhibiting inhibition at 16 μM for S.
aureus. None of truncated analogs exhibited antimicrobial activity against any of the
strains tested at any of the concentrations indicated.
The MIC values were then used to determine if the addition of the second
antimicrobial species, silver nitrate, had any combinatorial effect on the bacteria species
tested. Tables 3-5 show the MIC of each antimicrobial species alone as well as the
combinatorial MIC for each full-length peptide. The combination of both silver and
peptides lowered the MIC values for all bacteria species when compared to either peptide
or silver nitrate alone.
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Table 2
MIC (μM) for S. aureus, E. coli, P. aeruginosa, and K. pneumoniae
S. aureus

E. coli

P. aeruginosa

K. pneumoniae

AP3

4.15

8.30

0.250

4.15

AP3K

2.32

9.30

0.290

>9.30

APX

16.6

>16.6

16.6

>16.6

APX-12

>15.0

>15.0

>15.0

>15.0

APX-17

>8.00

>8.00

> 8.00

>8.00

Table 3
Combinatorial MIC (μM) for S. aureus, E. coli, P. aeruginosa, and K. pneumonia with
AP3
MIC (μM) for S. aureus, E. coli, P. aeruginosa, and K. pneumoniae
S. aureus

E. coli

P. aeruginosa

K.
pneumoniae

4.15

8.30

0.25

4.15

50

12.5

25

12.5

Silver Nitrate
(w/Constant 2 μM
AP3)

<1.5

<1.5

<1.5

<1.5

AP3 (w/ Constant 5
μM Silver Nitrate)

<0.23

<0.23

<0.23

0.46

AP3
Silver Nitrate
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Table 4
Combinatorial MIC (μM) for S. aureus, E. coli, P. aeruginosa, and K. pneumonia with
AP3K
MIC (μM) for S. aureus, E. coli, P. aeruginosa, and K. pneumoniae
S. aureus

E. coli

P. aeruginosa

K.
pneumoniae

2.32

9.3

0.29

>9.30

50

12.5

25

12.5

Silver Nitrate
(w/Constant 2 μM
AP3K)

<1.5

<1.5

<1.5

<1.5

AP3K (w/ Constant 5
μM Silver Nitrate)

<0.15

<0.15

<0.15

<0.15

AP3K
Silver Nitrate

Table 5
Combinatorial MIC (μM) for S. aureus, E. coli, P. aeruginosa, and K. pneumonia with
APX
MIC (μM) for S. aureus, E. coli, P. aeruginosa, and K. pneumoniae
S. aureus

E. coli

P. aeruginosa

K.
pneumoniae

16.6

>16.60

16.6

>16.60

50

12.5

25

12.5

Silver Nitrate
(w/Constant 2 μM APX)

<1.5

<1.5

<1.5

<1.5

APX (w/ Constant 5 μM
Silver Nitrate)

<0.15

<0.15

<0.15

<0.15

APX
Silver Nitrate
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Lipid binding. Current understanding of antimicrobial peptide mechanism of
action involves the binding of peptides to the bacterial membrane as the first step in the
bactericidal activity. Binding experiments were designed to monitor the interactions of
the AP peptides with model lipid bilayers. This was approached using tryptophan
emission fluorescence spectroscopy due to the environmental sensitivity of tryptophan
fluorescence. This sensitivity is often exploited to discriminate between the polar milieu
and the more nonpolar lipid bilayer environments. Model vesicles were composed of
either 100% PC or 75/25% PC/PG lipids to investigate the effect of electrostatics on the
binding of peptides to bilayers. The electrostatic binding mechanism is widely accepted
as a major component of the selectivity of antimicrobial peptides (bacterial membranes
contain high mole fractions of anionic lipids imparting a strongly negative net charge to
their cell surface)[61],[62]. However our results show that only the original parent
sequence AP3 exhibited any significant shift in emission barycenter when interacting
with lipid vesicles as shown in Figures 7 and 8. However peptides other than AP3 all
exhibited significant changes in emission intensity upon introduction of lipid vesicles
which is likely a result of binding interaction (Figure 6). Interestingly, none of the
peptides in this study showed any significant preference between zwitterionic POPC
vesicles and vesicles composed of 75%/25% POPC/POPG.
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Figure 6. Peptide Binding to Lipid Vesicles. Peptide interaction with lipid vesicles was
monitored using Trp emission spectra. The normalized Trp emission intensity is shown
for each AP peptide titrated with either 75/25% PCPG (A) or 100% PC (B) lipid vesicles.
For both graphs, AP3 is shown as diamonds (), AP3K as squares (), APX as triangle
(), APX-12 as open circle (), and APX-17 as closed circles (). Peptide
concentration was 2 μM in all cases. Data shown are corrected for background
fluorescence and represent averages of at least three replicate samples.
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Figure 7. Peptide Binding to Lipid Vesicles by Spectral Shifts. Binding of AP peptides to
lipid vesicles analyzed by change in emission spectrum barycenter as a function of lipid
concentration. Each peptide was titrated with either 75:25 PC:PG (A) and 100 PC (B)
vesicles. For both graphs, AP3 is shown as diamonds (), AP3K as squares (), APX
as triangle (), APX-17 as open circle (), and APX-12 as closed circles (). Peptide
concentration was 2 μM in all cases. Data shown are corrected for background
fluorescence and represent averages of at least three replicate samples.
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Figure 8. Barycenter Shift. Barycenter shift of AP peptides and derivatives at lipid
vesicles at concentrations of 0 and 300 μM. Lipid compositions titrated were 75:25
PC:PG. Data are averages of at least three replicate samples. Parent peptide AP3 exhibits
the greatest barycenter shift indicating the largest change in polarity of the local
environment around Trp.

Fluorescence quenching. While the titrations described above indicate that all
the peptides in this study interact with lipid membranes, the topography and structural
orientation of peptides associated with the bilayer may be different among the different
peptides. Changes in peptide orientation with respect to the bilayer can impact
fluorescence properties as well as be related to the mechanism of action. Fluorescence
quenching experiments were performed to gain insight on the origination in the bilayer.
Tryptophan fluorescence quenching was performed by using the collisional quencher
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acrylamide, which can strongly quench tryptophan exposed to the aqueous environments
however results in very minimal quenching of tryptophan residues buried in the nonpolar
core of the bilayer[58],[63]. Quenching of the peptides were compared in the presence
and absence of lipid vesicles. For the full length peptides, AP3 and APX were more
strongly quenched in the absence of lipid compared to presence of lipid, indicating a
greater degree of occlusion of the tryptophan when bound to the lipid bilayer (Figure 9).
Interestingly the AP3K peptide showed very little difference in quenching profile with
and without lipid indicating that the AP3K peptide may adopt a different 3D topography
when bound to the bilayer compared to AP3 and APX (Figure 9). Truncated analogs of
APX show similar results to AP3K in that there was no significant difference in
quenching between the bound and unbound samples. This is indicative that, when bound,
the AP3K and the truncated analogs adopt a structure that orients the tryptophan more
shallowly in the bilayer increasing the exposure to acrylamide in the aqueous
environment.

26

Figure 9. Fluorescence Quenching. Fluorescence quenching of AP3 and derivatives by
acrylamide in the presence (A) or absence (B) of lipid vesicles. For both graphs, AP3 is
shown as diamonds (), AP3K as squares (), APX as triangle (), APX-17 as open
circle (), and APX-12 as closed circles (). Quenching of 2 μM peptide at pH 7 is
shown in the presence of 75:25% POPC:POPG vesicles and100% POPC vesicles both
totaling a final concentration of 250 μM. Data shown are corrected for background
fluorescence, inner filter effects, and are averages of at least three replicate samples.
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Circular dichroism. CD spectra were collected for peptides dissolved in pH 7
buffer, pH 7 buffer with lipid vesicles (75/25% PC/PG) or pH 7 buffer and TFE (50/50
buffer/TFE). TFE is known to promote helical structure and is used as a control. In buffer
all peptides exhibited CD signatures consistent with random coil structure (minima ~198
nm). When bound to lipid vesicles, all of the full length peptides displayed CD spectral
consistent with the formation of α-helical secondary structure (minima 208 and 222 nm)
(Figure 10). Interestingly APX-17 showed less helical character than the shorter APX-12
which was clearly adopting helical structure. As anticipated, all peptides were shown to
adopt a helical confirmation when in the presence of TFE.
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Figure 10. Circular Dichroism. Circular dichroism spectra of 5 μM (A) AP3, (B) AP3K,
(C) APX, (D) APX-17, or (E) APX-12 Spectra were recorded in the presence of pH7
buffer, 1:1 TFE:pH7 buffer, or 250 μM 75:25 PC:PG SUVs. All spectra are averages of
64 scans and were background subtracted. For all graphs, buffer is shown as dots, TFE as
dashes, and Lipid as solid line.
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Calcein leakage. Bilayer disruption and or pore formation is commonly proposed
to be a component of the mechanism of action of antimicrobial peptides. Calcein leakage
assays were performed to determine if AP3 and analogs are capable of causing bilayer
disruption allowing molecules to cross the membrane[64],[65]. In this assay, the
fluorophore calcein is entrapped within lipid vesicles where fluorescence emission is
strongly quenched through a self-quenching mechanism. If peptides induce bilayer
disruption or create sufficiently large pores in the bilayer, the entrapped calcein can leak
out of the vesicle lumen thus relieving the self-quenching and resulting in an increased in
calcein fluorescence emission intensity. Leakage assays were performed using 75%/25%
PC/PG vesicles and leakage was monitored over the course of 30 minutes, however the
samples reached steady state after no more than 5 minutes in all cases. Full release was
determined by adding an aliquot of the detergent Triton X-100 to each well after the 30
minute time course. The full-length peptides exhibit similar dose dependent vesicle
permeabilization activity with near complete permeabilization achieved between 0.1-1
μM peptide. (Figure 11 and 12). Notably the truncated peptides induced minimal if any
leakage even at the highest concentrations tested.
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Figure 11. Vesicle Leakage Assay. Leakage of calcein entrapped in 75:25 PC:PG lipid
vesicles after exposure to peptides. Percent leakage was calculated at 5 (A) and 30(B)
minutes post addition of peptide. For both graphs, AP3 is shown as diamonds (),
AP3K as squares (☐), APX as triangle (Δ), APX-17 as open circle (), and APX-12 as
closed circles (). Lipid concentration in the sample was 200 μM Percent leakage was
calculated by treating each sample with Triton X-100 and remeasuring fluorescence
which was then set to 100% leakage. Each point represents the average of at least 3
replicate samples.
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Figure 12. Calcein Leakage as a Function of Peptide/Lipid Concentration. Leakage of
calcein entrapped in 75:25 PC:PG lipid vesicles after exposure to peptides. Percent
leakage, as a function of peptide/lipid concentration, was calculated at 5 (A) and 30(B)
minutes post addition of peptide. For both graphs AP3 is shown as diamonds (), AP3K
as squares (), APX as triangle (), APX-17 as open circle (), and APX-12 as closed
circles (). Lipid concentration in the sample was 200 μM Percent leakage was
calculated by treating each sample with Triton X-100 and remeasuring fluorescence
which was then set to 100% leakage. Each point represents the average of at least 3
replicate samples.
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Bacterial membrane permeabilization. Based on the results of the calcein
leakage assays, permeabilization of live, intact E. coli was investigated using enzyme
based leakage assays. Briefly these assay rely on limited diffusion of a chromogenic
substrate across a bacterial membrane(s). If the membrane(s) are disrupted by an
antimicrobial peptide (or other agent) the substrate can more easily transit across the
membrane(s) where it can be broken down by a bacterially expressed enzyme. The assay
for outer membrane permeabilization relies on the enzyme β-lactamase, located in the E.
coli periplasmic space, which can cleave the β-lactam containing molecule nitrocefin.
The nitrocefin break down results in a chromogenic product[57],[66]. Bacteria were
exposed to varying concentrations of the AP peptides and nitrocefin cleavage was
monitored over a 90 minute time course. Figure 14 represents the data collected after 30
minutes of the assay (this was after samples had reached steady state) (Figure 13). The
parent peptide AP3 exhibited the highest degree of bacterial membrane disruption
followed closely by the other full-length peptides. Consistent with the calcein leakage
data, the truncated peptides showed little to no disruption at any of the concentrations
tested.
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Figure 13. Outer-Membrane Permeability-Full Time Course. Outer-membrane
permeability of E. coli after treatment with peptides (A) AP3, (B) AP3K, (C) APX, (D)
APX-17, (E) APX-12 or (F) the control (Polymixin B). For all graphs peptide
concentration 15 μM is shown as diamonds (), 7.50 μM as squares (), 3.75 μM as
triangle (), 1.88 μM as (X), 0.94 μM as (*), 0.47 μM as closed circles (), 0.23 μM as
(+) and 0 μM as (-). Samples contained 50μg/mL nitrocefin, and 80μL of resuspended E
coli cell suspension, and 10 μL peptide from a stock solution for the appropriate final
concentration. Absorbance values shown represent data collected over 90 minutes of
exposure to peptide. Data are averages of at least three replicate samples.
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Figure 14. Outer-Membrane Permeability. Outer-membrane permeability of E. coli after
treatment with peptides. For both graphs AP3 is shown as diamonds (), AP3K as
squares (), APX as triangle (), APX-17 as open circle (), and APX-12 as closed
circles (). Samples contained 50 μg/mL nitrocefin, and 80 μL of resuspended E coli cell
suspension, and 10 μL peptide from a stock solution for the appropriate final
concentration. Absorbance values shown represent data collected after 30 minutes of
exposure to peptide. Data are averages of at least three replicate samples.
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The assay for inner membrane permeabilization relies on the enzyme βgalactosidase, located in the E. coli inner membrane, which can cleave the molecule
ONPG a chromogenic mimic of the natural substrate lactose. Similarly the ONPG
cleavage results in a chromogenic product[57],[66]. Bacteria were exposed to varying
concentrations of the AP peptides and ONPG break down was monitored over a 90
minute time course. Figure 16 represents the data collected after 30 minutes of the assay
(this was after samples had reached steady state, Figure 15). Consistent with the results of
the outer membrane permeabilization experiments, the parent peptide AP3 exhibited the
highest degree of bacterial membrane disruption followed closely by the other full length
peptides and little to no disruption induced by the truncated peptides.
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Figure 15. Inner-Membrane Permeability-Full Time Course. Inner-membrane
permeability of E. coli after treatment with peptides (A) AP3, (B) AP3K, (C) APX, (D)
APX-17, (E) APX-12 or (F) the control(C-Tab). For all graphs peptide concentration 15
μM is shown as diamonds (), 7.50 μM as squares (), 3.75 μM as triangle (), 1.88
μM as (X), 0.94 μM as (*), 0.47 μM as closed circles (), 0.23 μM as (+) and 0 μM as (). Samples contained 56.25μL Z-buffer (100 mM Na2HPO4, 10 mM KCl, 1 mM MgSO4,
40 mM β– mercaptoethanol, pH 7.1), 12μL ONPG (4mg/ml), 18.75μL E. coli, (5.0 x 105
cfu/ml) and 10μL of peptide from the appropriate final concentrations. Absorbance
values shown represents data collected after 90 minutes of exposure of peptide. Data are
averages of at least three replicate samples.
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Figure 16. Inner-Membrane Permeability. Inner-membrane permeability of E. coli after
treatment with peptides. For both graphs AP3 is shown as diamonds (), AP3K as
squares (), APX as triangle (), APX-17 as open circle (), and APX-12 as closed
circles (). Samples contained 56.25L Z-buffer (100 mM Na2HPO4, 10 mM KCl, 1
mM MgSO4, 40 mM β– mercaptoethanol, pH 7.1), 12μL ONPG (4mg/ml), 18.75L E.
coli, (5.0 x 105 cfu/ml) and 10μL of peptide from the appropriate final concentrations.
Absorbance values shown represents data collected after 30 minutes of exposure of
peptide. Data are averages of at least three replicate samples.

Mammalian cell viability. An MTT assay was performed to determine if the
peptides exhibited any toxicity toward mammalian cells, in this case HEK-293 cells. The
cells were treated with five different concentrations of each peptide ranging from 0.0015
µM to 15 µM. The results show that the peptides did not have any major inhibitory effect
on the growth or viability of HEK-293 cells at the effective MIC concentrations
(approximately 80 percent viable cells for AP3 and AP3K) (Figure 17)[67],[68],[69].
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Figure 17. MTT Assay. Viability of human embryonic kidney HEK293 cells (1.5x104)
measured with MTT assay after treatment of peptides and 24 h incubation. Peptides are
represented as AP3 (black), AP3K (diagonal line), APX (gray), APX-17 (vertical lines)
and APX-12 (white). Data are averages of at least three replicate samples.

Discussion
Antimicrobial resistance has become a global problem and the need for a solution
by minimizing the amount of resistant bacteria has become crucial[4]. Finding
alternatives to the use of antibiotics is a strategy that has been used to try and minimize
the problem of resistance. Antimicrobial peptides are one class of molecules that have
been investigated due to their low propensity for resistance along with their ability to kill
or inhibit bacterial growth[26, 35]. We attempted to use this strategy to further explore a
relatively unknown antimicrobial peptide along with various analogs. In an attempt to
further enhance the efficacy of the peptides, a second antimicrobial agent, silver, was
added to determine whether a synergistic relationship exists.
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The data indicated all the peptides in this study interacted with lipid bilayers with
similar affinities. This is interesting because, unlike many cationic AMPs, the inclusion
of anionic lipids (POPG in our study) did not have a significant effect on lipid binding.
Numerous reports indicate the increase in anionic lipid concentration increases the
affinity for peptides for lipid bilayers[70],[71],[72]. The binding enhancement cause by
inclusion of anionic lipid in a bilayer is driven by electrostatic interactions between
cationic AMP and the anionic lipid surface, which mimics the bacterial cell surface[32].
Our results show even the truncated peptides, with decreased net positive charge,
effectively bound to lipid bilayers over similar concentration ranges to the full length
analogs (Figure 6), which is similar to behavior of LL-II and MSI-78 peptides[73],[74].
Additionally, penetratin and its truncates showed preferential binding to POPC/POPG
membranes over DMPC/DMPG bilayers indicating a bilayer thickness effect[75]. The
ability for peptides to span the bilayer is thought to be a component, or at least related to,
the ability to disrupt lipid bilayer integrity and thus a link to hydrophobic matching is not
unexpected[35],[71],[76].
Circular dichroism results indicate a clear formation of α-helical secondary
structure for all AP3 peptides examined when they were bound to model lipid bilayers.
This is consistent with numerous reports in the literature, indicating a random coil to
helical confirmation change for cationic AMPs upon binding to lipid bilayers[57],[77].
Interestingly, the truncated peptides also adopted an α-helical confirmation when bound
to a lipid bilayer, although to a lesser extent as evidenced by the lower mean residue
ellipticity values[74]. This indicates the loss of hydrophobic and cationic groups does not
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completely interfere with the ability of these peptides to adopt α-helical secondary
structure[74].
For most antimicrobial peptides there is a clear facially amphiphilic structure
when the peptide adopts an α-helical confirmation. Generally, cationic residues segregate
to one face of the helix and hydrophobic moieties segregate to the opposite face[78,
79],[80]. However there is very little description in the literature of peptides that exhibit
antimicrobial activity but do not adopt facially amphiphilic structures. Many reports
focus on the facially amphiphillic structure as a necessary component of antimicrobial
activity in peptides and polymers, often using non-facially amphiphillic controls which
exhibit decreased efficacy. As seen in Figure 4, the AP3 and derivative peptides do not
show any facial amphiphilicity, which could be tied to the insensitivity to anionic lipid
composition. As the peptides are truncated, they lose both hydrophobic and cationic
residues but this loss does not significantly effect the overall distribution of groups
around the peptide helical axis. As such, it appears the hydrophobic burial interactions
drive the binding of these peptides to the bilayer.
The binding to lipid membranes and helix formation in the AP3 peptides indicates
they are behaving somewhat similar to traditional amphiphilic AMPs. However the lack
of facial amphiphilicity presents an interesting question regarding how these peptides
orient on/in the lipid bilayer. The lack of facial amphiphilicity makes traditional
hydrophobic residue partitioning into the lipid bilayer difficult without also resulting in
some burial of some hydrophilic groups. Acrylamide, an aqueous quencher of tryptophan
fluorescence, was used to assay the orientation and topology of the AP3 peptides when
bound to lipid bilayers. Strikingly the full-length peptides exhibited significantly different
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quenching patterns compared to the truncated peptides. This indicates while all the
peptides sequences studied bind to lipid bilayers, the final conformation at the bilayer
surface is clearly different. Notably, the APX peptide series have the Trp at position 2
while the AP3 and AP3K have the Trp reporter at position 22, meaning in either a
transmembrane or surface orientation, the Trp residue should be somewhat exposed to the
aqueous milieu. The observed differences could be attributed to altering the
charge/hydrophobic balance or as a result of hydrophobic mismatch between the shorter
peptides and the bilayer.
Bacterial membrane permeabilization and vesicle leakage assays yielded
consistent results in that full-length peptides caused a greater extent of leakage across the
bilayer(s) compared to the truncated peptides. These results indicate that if the length and
charge of an antimicrobial peptide is altered this can significantly lower the antimicrobial
effectiveness, and potentially the mechanism of action, may be affected as reported
elsewhere[81],[82, 83]. Depending on the mechanism of the shorten length of the
truncated peptides may impact the ability to disrupt bilayers due to effects arising form
hydrophobic mismatch[83],[84].
The MIC assay performed indicated the truncated peptides are less effective as
antimicrobial agents compared to the full-length sequence, which is consist with recent
reports in literature[85],[86],[87]. However, antimicrobial activity for AMPs is not
exclusively linked to peptide length, as many naturally occurring AMPs are as short as
the shortest sequences tested here[88],[89]. Similarly, reports in the literature have found
that by decreasing the overall net charge of cationic AMPs the efficacy is also frequently
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reduced[81]. The lack of antimicrobial activity for the truncated peptides in this study is
not surprising considering the inability to permeabilize bacterial membranes.
The AP3 derived peptides also showed little cytotoxic activity at effective
antimicrobial concentrations. This is consistent with the membrane permeabilization
activity. Many studies have linked the cytotoxic effects of AMPs and AMP mimetics to
hydrophobic interactions in which increased hydrophobic content is proportional to
increased cytotoxicity.
The AP3 and APX peptide comparison is of interest as the only difference
between these two peptides is the location of the Trp, yet there was a 4 fold difference in
S. aureus MIC values and at least a two fold difference in E. coli MIC values. They seem
to bind and quench similarly but have different permeabilization, This is surprising
considering the small differences in the quenching and binding. The behavior in the
leakage assay seems to mimic the behavior in the MIC assay more closely than the
binding or the quenching assays. This reinforces the value of extending biophysical
studies as well as natural membrane studies to better recapitulate the environment the
peptides would encounter.
Conclusions
From the combination of the results (summarized in Table 6 and 7), the AP3 and
derived peptides appear to bind to bilayers via hydrophobic interactions, but these
hydrophobic interactions are not sufficient to cause significant cytotoxicity to mammalian
cells or antibacterial activity in some cases. Additionally, binding to model lipid vesicles
did not predict antimicrobial activity nearly as well as leakage assays. These results
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highlight the delicate balance in structure activity relationships among antimicrobial
peptides and warrant more in depth investigations.

Table 6
Overview of Results for AP Peptides

AP3

AP3K

Fluorescence
Spectroscopy

Circular

MIC

MTT

Large barycenter shift,
indicating a change in
tryptophan environment
(small interaction with
lipid vesicles). No
binding preferences
between 75:25 PC:PG
and 100 PC lipid vesicles.

α helical
confirmation in
the presence of
TFE and 75:25
lipid vesicles

Lowest MIC (high
antimicrobial
activity) against all
organisms except

Low toxicity
at effective
MIC values
for HEK-293
cells

No barycenter shift,
indicating no change in
tryptophan environment
(small interaction with
lipid vesicles). No
binding preferences
between 75:25 PC:PG
and 100 PC lipid vesicles.

α helical
confirmation in
the presence of
TFE and 75:25
lipid vesicles

Low MIC (high
antimicrobial
activity) against S.
aureus and P.
aeruginosa.

Dichroism
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S. aureus

Low toxicity
at effective
MIC values
for HEK-293
cells

Table 6 (continued)
Fluorescence
Spectroscopy

Circular

MIC

MTT

APX

No barycenter shift,
indicating no change in
tryptophan environment
(small interaction with
lipid vesicles). No
binding preferences
between 75:25 PC:PG
and 100 PC lipid vesicles.

α helical
confirmation in
the presence of
TFE and 75:25
lipid vesicles

No measureable
MIC value for E.
coli, K. pneumonia
and high MIC (low
activity) for S.
aureus and P.
aeruginosa

Low toxicity
for HEK-293
cells

APX-12

No barycenter shift,
indicating no change in
tryptophan environment
(small interaction with
lipid vesicles). No
binding preferences
between 75:25 PC:PG
and 100 PC lipid vesicles.

α helical
confirmation in
the presence of
TFE and 75:25
lipid vesicles

No measureable
MIC value
measured

Low toxicity
for HEK-293
cells

APX-17

No barycenter shift,
indicating no change in
tryptophan environment
(small interaction with
lipid vesicles). No
binding preferences
between 75:25 PC:PG
and 100 PC lipid vesicles.

α helical
confirmation in
the presence of
TFE and 75:25
lipid vesicles

No measureable
MIC value
measured

Low toxicity
for HEK-293
cells

Dichroism
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Table 7
Overview of Leakage and Permeabilization Results for AP Peptides
Calcein Leakage

Outer

Inner.

Permeabilization

Permeabilization

AP3

High (greatest of all
peptide tested)

High (greatest of all
peptides tested)

High (greatest of all
peptides tested)

AP3K

High/moderate

Moderate/low

Moderate/low

APX

High/moderate

Moderate/low

Moderate/low

APX-12

Low/minimal

Low/little

Low/little

APX-17

Low/minimal

Low/little

Low/little
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Chapter 3
Characterization, Antimicrobial Activity and Synergistic Effect of Decoralin and
Silver Nitrate
Introduction
Venomous arthropods often produce venom mixtures that include peptides with
antimicrobial activity. These complex venoms are naturally used to suppress prey[47].
The venom of the solitary eumenine wasp, Oreumenes decoratus is a mixture that
includes an 11 residue peptide with is commonly referred to as decoralin[33]. Decoralin
has been characterized as a linear, cationic alpha-helical peptide consisting of
hydrophobic and basic amino acids[33]. Synthetic analogs of the original decoralin
sequence have been characterized and the biological activities investigated[33]. In a study
preformed by Konno et al., the C-terminus of decoralin was amidated, resulting in higher
level of helicity and decreased hemolytic activity when compared to the original
sequence[33].

The amidated analog of decoralin also showed greater antimicrobial

activity against both Gram positive and Gram-negative bacteria[33]. These results show a
great potential for decoralin analogs being a good template for new drug targets in
combating antibiotic resistance.
In our current study, the original decoralin sequence has been modified to include
a tryptophan residue in place of isoleucine. This analog was designed because tryptophan
is a good reporter in fluorescence assays. The modified sequence of decoralin is shown in
Table 8.
fluorescence

This modified sequence was then tested in various assays including
spectroscopy,

circular

dichroism

(CD)

spectroscopy,

vesicle

permeabilization assays, bacterial permeabilization assays, and minimal inhibitory
concentration (MIC) assays to further characterize this venom peptide.
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Material and Methods
Bacterial culturing. Prepared using the procedure described in Chapter 2.
Minimum inhibitory assay (MIC). Same procedure performed as described in
Chapter 2.
Lipid preparation. Prepared using the procedure as described in Chapter 2.
Binding experiments. Same procedure performed as described in Chapter 2.
Acrylamide quenching. Same procedure performed as described in Chapter 2.
Circular dichroism. Same procedure performed as described in Chapter 2.
Calcein leakage assay. Same procedure performed as described in Chapter 2.
Bacterial outer membrane permeabilization assay. Same procedure performed
as described in Chapter 2.
Bacterial inner membrane permeabilization assay. Same procedure performed
as described in Chapter 2.
Bacterial growth analysis. Dilutions were grown to OD600 0.2 - 0.3 before being
diluted a second time to a range calculated by the experiment being performed.
Calculations were performed using the conversion factors of OD600 = 1.0 is equivalent to
~108 CFU/mL for S. aureus and K. pneumoniae and ~109 CFU/mL for E.coli and P.
aeruginosa[90],[91],[92].
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Synergy assay. Assays for synergistic interactions between peptides and Ag+
were performed using the checkerboard microdilution method[93],[94]. Briefly, plates
are set up similarly to the MIC assay, however combinations of antimicrobial peptides
and AgNO3 were added to the wells.
Results
Lipid binding. As described in Chapter 2, binding experiments were used to
investigate the interaction between the peptide decoralin with model lipid bilayer. Since
the modified decoralin sequence contains a tryptophan residue, tryptophan emission
fluorescence spectroscopy was used to monitor the environmental changes of the peptide.
Model vesicles were composed of either 100% PC or 75/25% PC/PG lipids to investigate
the effect of electrostatics on the binding of peptides to bilayers. Our results showed that
decoralin exhibited a shift in emission barycenter when bound to the 75%/25%
POPC/POPG lipid composition (Figure 18 and 19). In contrast the peptide exhibited less
shift in emission barycenter when titrated with 100% PC, vesicles indicating the peptide
likely adopts a somewhat different orientation at the bilayer surface in these vesicles.
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Figure18. Decoralin Binding to Lipid Vesicles by Spectral Shifts. Binding of decoralin to
lipid vesicles analyzed by change in emission spectrum barycenter as a function of lipid
concentration. Decoralin was titrated with either 75:25 PC:PG () and 100 PC ()
vesicles. Peptide concentration was 2 μM both cases. Data shown are corrected for
background fluorescence and represent averages of at least three replicate samples.
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Figure 19. Barycenter Shift of Decoralin. Barycenter shift of decoralin at lipid vesicles at
concentrations of 0, 90, and 300 μM. Lipid compositions titrated were 75:25 PC:PG.
Data are averages of at least three replicate samples.

Fluorescence quenching. In an attempt to analyze the topography of decoralin on
the bilayer surface, fluorescence quenching experiments were performed. The aqueous
quencher acrylamide was chosen as it effectively quenches tryptophan and can readily
pass across lipid bilayers. The results of quenching experiments in the absence and
presence of PC/PG vesicles are shown. The results indicate there is little difference in
quenching, thus the tryptophan appears to be very accessible to aqueous environments
and therefore the acrylamide quencher, in both bound and unbound states (Figure 20).
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Figure 20. Fluorescence Quenching of Decoralin. Fluorescence quenching of decoralin
by acrylamide in the presence () or absence () of lipid vesicles. Quenching of 2 μM
peptide at pH 7 is shown in the presence of 75:25 POPC:POPG vesicles and100 POPC
vesicles both totaling a final concentration of 250 μM. Data shown are corrected for
background fluorescence, inner filter effects, and are averages of at least three replicate
samples.

Circular dichroism. CD spectra were collected for peptides dissolved in pH 7
buffer, pH 7 buffer with lipid vesicles (75/25% PC/PG) or pH 7 buffer and TFE (50/50
buffer/TFE). TFE is known to promote helical structures and is used as a comparison. In
buffer, decoralin exhibited CD spectra consistent with a random coil structure (minimum
at ~198 nm), in the presence of TFE exhibited decoralin exhibited CD spectral consistent
with the formation of α-helical secondary structure (minima 208 and 222 nm) (Figure
21).

In the presence of lipid vesicles, the peptide clearly adopts an α-helical
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confirmation, consistent with the behavior of many known membrane disruptive peptides
such as melittin and magainin.

Figure 21. Circular Dichroism of Decoralin. Circular dichroism spectra of 5 μM
decoralin. Spectra were recorded in the presence of pH7 buffer, 1:1 TFE:pH7 buffer, or
250 μM 75:25 PC:PG SUVs. All spectra are averages of 64 scans and were background
subtracted. For all graphs, buffer is shown as dots, TFE as dashes, and Lipid as solid line.
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Calcein leakage. Calcein leakage assays were performed on decoralin to
determine the ability to disrupt model lipid vesicles (75%/25% PC/PG). At the highest
peptide concentration tested, decoralin exhibited moderate bilayer disruption (~60 to 70
percent release) at both the 5 and 30 minutes time points (Figure 22). As seen with the
AP peptides, steady-state was achieved shortly after the peptide was added resulting in a
small between the 5 and 30 minute time points. Leakage was also determined for another
insect-derived peptide, L1. This peptide is significant longer than the decoralin sequence
and thus may have different interacting properties. This peptide exhibited slightly lower
peptide induced leakage from vesicles.
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Figure 22. Vesicle Leakage Assay of Decoralin and L1. Leakage of calcein entrapped in
75:25 PC:PG lipid vesicles after exposure to peptides. Percent leakage of lipid after
exposure of decoralin (A) and L1 (B). For both graphs, 5 minutes of leakage is shown as
diamonds (), and 30 minutes of leakage as squares (). Lipid concentration in the
sample was 200 μM Percent leakage was calculated by treating each sample with Triton
X-100 and remeasuring fluorescence which was then set to 100% leakage. Each point
represents the average of at least 3 replicate samples.
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Bacterial membrane permeabilization. As described previously, bacterial
membrane permeabilization was used to further investigate the membrane disruption
ability of peptide in question. These experiments provide a more authentic evaluation of
whether a peptide can disrupt natural bacteria membranes. Consistent with calcein
leakage assays, decoralin showed moderate amount of membranes disruption only at the
highest concentrations tested (Figure 23 and 24). For both the outer and inner membrane
permeabilization was time dependent with the continuing increase in chromophore
conversion over the entire 90 minute time course study.
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Figure 23. Outer-Membrane Permeability of E. coli With Decoralin. Absorbance values
shown represent data collected over 90 minutes (A) and 30 minutes (B) of exposure to
decoralin. For graph (A) peptide concentration 15 μM is shown as diamonds (), 7.50
μM as squares (), 3.75 μM as triangle (), 1.88 μM as (X), 0.94 μM as (*), 0.47 μM as
closed circles (), 0.23 μM as (+) and 0 μM as (-). Samples contained 50 μg/mL
nitrocefin, and 80 μL of resuspended E coli cell suspension, and 10 μL peptide from a
stock solution for the appropriate final concentration. Data are averages of at least three
replicate samples.
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Figure 24. Inner-Membrane Permeability of E. coli With Decoralin. Absorbance values
shown represent data collected over 90 minutes (A) and 30 minutes (B) of exposure to
decoralin. For graph (A) peptide concentration 15 μM is shown as diamonds (), 7.50
μM as squares (), 3.75 μM as triangle (), 1.88 μM as (X), 0.94 μM as (*), 0.47 μM as
closed circles (), 0.23 μM as (+) and 0 μM as (-). Samples contained 56.25μL Z-buffer
(100 mM Na2HPO4, 10 mM KCl, 1 mM MgSO4, 40 mM β– mercaptoethanol, pH 7.1), 12
μL ONPG (4 mg/mL), 18.75 μL E. coli, (5.0 x 105 CFU/mL) and 10 μL of peptide from
the appropriate final concentrations. Data are averages of at least three replicate samples.
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Antibacterial activity. MIC assays were performed to determine the efficacy of
decoralin against various Gram-negative and Gram-positive bacteria. Decoralin had the
lowest MIC (highest activity) against E. coli exhibiting an MIC of approximately 5μM
and a two-fold increase of 10 μM against S. aureus. The bacterial species P. aeruginosa
and K. pneumonia were also tested but decorlain exhibited no antimicrobial activity
against these species for the concentrations tested. MIC values were also determined for
the L1 peptide, which exhibited the lowest MIC values for E. coli and S. aureus at
approximately 1.81μM and 7.25μM respectively. In contrast L1 was active against K.
pneumonia and P. aeruginosa exhibiting an MIC of 14.5μM in both cases. MIC assays
were also performed using the small molecule silver nitrate, which exhibited activity
against all species tested ranging from 12.5 to 50 μM (Table 8 and 9).
Combinatorial MIC were performed with peptides and silver nitrate to determine
if antimicrobial synergy between these compounds exist. L1, and silver nitrate alone,
combinatorial MIC assays were performed to see if an enhanced efficacy existed. The
combination of both silver and peptides (decoralin or L1) lowered the MIC values for the
bacteria species E. coli and S. aureus when compared to either peptide or silver nitrate
alone(Table 8 and 9). In contrast, the MIC against P. aeruginosa and K. pneumonia
remained unchanged or were only slightly affected by the presence of both antimicrobial
species.
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Table 8
Combinatorial MIC (μM) for S. aureus, E. coli, P. aeruginosa, and K. pneumonia with
Decoralin
MIC (μM) for S. aureus, E. coli, P. aeruginosa, and K. pneumoniae
S. aureus

E. coli

P. aeruginosa

K. pneumoniae

Decoralin

10

5

>10

>10

Silver Nitrate

50

25

25

25

12.5

6.25

>10

6.25

5

0.625

>10

>10

Silver Nitrate
(w/Constant 2 μM
Decoralin)
Decoralin (w/ Constant
5 μM Silver Nitrate)
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Table 9
Combinatorial MIC (μM) for S. aureus, E. coli, P. aeruginosa, and K. pneumonia with
L1
MIC (μM) for S. aureus, E. coli, P. aeruginosa, and K. pneumoniae
S. aureus

E. coli

P.
aeruginosa

K.
pneumoniae

7.25

1.8125

14.5

14.5

50

12.5

25

12.5

Silver Nitrate
(w/Constant 2 μM L1)

12.5

0.39

12.5

6.25

L1 (w/ Constant 5 μM
Silver Nitrate)

5

1.25

14.5

14.5

L1
Silver Nitrate

Bacterial growth kinetics experiments were performed to observe the effects of
the decoralin and silver nitrate in a liquid culture of bacteria. Kinetic experiments were
performed over a three hour time period comparing bacterial growth in an untreated
control to that in the presence of decoralin silver nitrate or both. The preliminary results
show that the S. aureus was most affected by the combination of silver nitrate and
decoralin compared to either treatment alone, indicating an additive or synergistic
activity. In contrast, the E. coli culture exhibited no inhibition of growth under the
conditions tested (Figure 25).
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Figure 25. Kinetics of E. coli and S. aureus With Decoralin. Growth kinetics of E. coli
and S. aureus after the addition of decoralin. Bacterial dilutions grown to OD600 0.2 - 0.3
before being diluted a second time to a range calculated by the experiment being
performed. Calculations were performed using the conversion factors of OD600 = 1.0 is
equivalent to ~108 CFU/mL for S. aureus and ~109 CFU/mL for E.coli. Four samples
were used; control (just bacterial) shown as diamonds (), bacteria combined with silver
nitrate shown as squares (), bacteria combined with decoralin shown as triangle ()
and bacterial, silver nitrate and decoralin shown as (X). Kinetics experiments were
performed over 3 hour time period with absorbance readings taken every 15 minutes.
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Potential synergistic interactions were investigated using checkerboard
assays[95-97]. Briefly these assays are set up to vary two different components added to
a bacterial culture to evaluate effects of interactions. These assays were performed using
varying concentration of both silver nitrate and peptide to determine whether the
combination had an enhanced antimicrobial effect. The peptide decoralin was tested and
the results showed no synergistic effect. This was also found to be the case for the L1
peptide against E. coli. Although no synergistic effect was observed, there appears to be
some additive effects, consistent with results in Figure 26 and 27, with the MIC values
being lower in the presence of both antimicrobial species.
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Figure 26. Synergy of Decoralin and Silver Nitrate. Synergistic assay of the peptide
Decoralin with the addition Silver Nitrate. Assay was done using the bacteria species S.
Aureus. Assay plate was made by adding 10 μL of the diluted peptide stock solutions, 10
μL of varying silver nitrate concentration and then 80 μL of diluted bacterial culture. The
final bacterial load was ~5.0 x 105 cfu/mL as calculated from OD600 measurements of a
log-phase culture. The assay plate was incubated at 37 °C for 18 h. Bacterial growth was
assayed by absorbance at OD600.
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Figure 27. Synergy of L1 and Silver Nitrate. Synergistic assay of the peptide L1 with the
addition Silver Nitrate. Assay was done using the bacteria species E. Coli. Assay plate
was made by adding 10 μL of the diluted peptide stock solutions, 10 μL of varying silver
nitrate concentration and then 80 μL of diluted bacterial culture. The final bacterial load
was ~5.0 x 105 cfu/mL as calculated from OD600 measurements of a log-phase culture.
The assay plate was incubated at 37 °C for 18 h. Bacterial growth was assayed by
absorbance at OD600.

65

Discussion
Antimicrobial peptides have been of great interest for development into
therapeutics because of the broad spectrum of antimicrobial activity these molecules
exhibit. There are also remaining questions over the mechanism of action of these
peptides, especially considering the evolutionary diversity seen in nature. Additionally
antimicrobial peptides are derived from multiple sources including host defense peptides
and peptides from venom, which in turn may act through different mechanism based on
their origin. As such, it’s of great interest to compare peptides from these different
classes. Specifically the relationship between sequence and mechanism of action may
differ between the classes as well as potential to the peptide and the second is being the
potential for these peptides to interact with each other and other antimicrobial agents to
exert combinatorial effect.
The linear cationic peptide decoralin which was originally isolated from the
venom of the solitary eumenine wasp Oreumenes decoratus was chosen to investigate as
a comparison to the truncated AP peptides. Decoralin is a short peptide (11 amino acid
residues) that exhibited antimicrobial activity against some of bacterial species tested.
Decoralin is a short peptide therefore may act via a mechanism of action that is different
when compared to longer peptides such as AP3. In addition, the truncated APX-12 and
APX-17 exhibited lost antimicrobial activity when the amino acid sequence was
shortened from the originals APX sequence. The contrast between the APX-12 peptide
and decoralin presents an interesting question on sequence and mechanism of action. We
wanted to investigate and compare the size and charges of each of these peptides to
determine how these characteristics affected the antimicrobial activity. In addition, we
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also investigated the slightly longer antimicrobial peptide, L1, which is also a venomous
insect derived peptide like decoralin. These were used in comparison to the AP peptide
which are host defense peptides.
In this study we investigated a several antimicrobial peptides and derivatives that
had different sequence lengths and net charges. Decoralin (venom derived) and APX-12
(host defense derived) are two short antimicrobial peptides which exhibited different
antimicrobial activity despite the similar length and net charge (Table 8). Although
decoralin didn’t exhibit the greatest antimicrobial activity of the peptides tested it did
show greater activity than the truncated peptide APX-12. Considering the similarly in
molecular weight and net charge (amino acid composition) this is an area of great interest
of future study to determine the molecular rules that in part antimicrobial activity to a
peptide sequence.
A similar approach was used when choosing and comparing the longer venom
derived peptide L1 to the full length AP3 and derivatives. The L1 peptide is originally
isolated from the venom of the predatory ant Pachycondyla goeldii and is a member of
the subfamily of Ponerinae[98, 99]. Ponericin peptides are thought to exhibit a defensive
role against microbial pathogens and are thought to adopt an amphipathic alpha-helical
structure[98].
The results of initial characterization experiments of the two groups of peptides
were compared. The data collected indicated that decoralin did bind to the model lipid
membranes and, unlike APX peptides, exhibited a shift in significant shift in emission
barycenter upon binding vesicles composed of 75%/25% POPC/POPG lipid composition.
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As expected the decrease in anionic lipids (POPG in our study) showed a decrease in
barycenter emission shift[70],[71],[72]. Although this is similar to other linear cationic
peptides these results contrast with the results of the APX truncated peptides.
Fluorescence quenching experiments for decoralin were found to be consistent with the
truncated AP peptides, in that there was no significant difference in quenching between
the bound and unbound samples. This indicates that these peptides adopt a shallowly
oriented topography in the bilayer where the tryptophan remains significantly exposed to
the aqueous environment. As expected, the results of CD spectra indicated decoralin
adopted α-helical secondary structure in the presence of model lipid membranes. This
was similar to the truncated APX peptides although the CD intensity was somewhat
lower for the APX peptides. Bacterial membrane permeabilization (outer and inner
membrane) and vesicle leakage assays showed moderate disruption compared to the AP
full-length peptides but were greater than both APX truncated analogs.

Table 10
APX-12 and Decoralin Comparison
Molecular Weight

Percent
Composition

Peptide

Sequence

Measured

Calculated

pI

Hydrophobic

APX-12

KTVGKLALKHWL

1393.7

1394.7

10.98

50%

Decoralin

SLLSLWRKLIT

1327.5

1329.6

11.39

54.55%
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Basic

Acidic

Neutral

33.33%

0%

16.67%

18.18%

0%

27.27%

Our study demonstrated a potentially additive interaction of silver nitrate with
either decoralin or L1. Identifying potential synergy between different antimicrobial
species has become an area of great interest due to the ongoing problem with antibiotic
resistance[4]. We chose silver nitrate because it is a broad spectrum antimicrobial like
antimicrobial peptides but are thought to act by a different mechanism therefore the
combination of the two could in theory have synergistic or additive effect. Our
preliminary results of decoralin and L1 indicate a potential additive effect but it is still
unclear if this effect can be categorized as synergistic. In future combinatorial
experiments the fractional inhibitory concentration index (FICI) will be used to determine
the degree of each combination of antimicrobials[93],[54]. FICI uses a combination of
MICs for each antimicrobial species to determine whether the combination results in a
synergistic, additive, or no effect. In future synergy studies we plan to use this method of
testing and FICI to calculate the degree of synergy.
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